Clinical studies of arbekacin sulfate in the pediatric field

R. Fujii, K. Fujita, Y. Sakata, T. Abe, T. Tajima, I. Terashima, H. Meguro, N. Watanabe, K. Mikuni, T. Sakai, N. Kasai, K. Sunakawa, S. Iwata, Y. Satoh, H. Akita, Y. Toyonaga, T. Ishihara, H. Nakamura, N. Iwai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRSA infections (pneumonia, septicemia, etc.) of pediatric patients. The obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0%. The efficacy rate by disease was 100%, 50.0% and 100% in septicemia, pneumonia, and urinary tract infection, respectively. The bacteriological eradications were obtained in 70.0% of the total patients; by disease, these rates were 100% and 50.0% in septicemia/urinary tract infection and in pneumonia, respectively. The MIC50 as well as the MIC80 against MRSA strains isolated from 9 patients were 0.39 μg/ml and 1.56 μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed γ-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: The pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. The C(max), 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. The T 1/2 's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5% of the dosages administered. In all cases, the urinary concentrations were highest in the first 2 hours, after the administration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.

Original languageEnglish
Pages (from-to)57-83
Number of pages27
JournalJapanese Journal of Antibiotics
Volume47
Issue number1
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Pediatrics
Sepsis
Pneumonia
Methicillin-Resistant Staphylococcus aureus
Urinary Tract Infections
Newborn Infant
Pharmacokinetics
habekacin
Clinical Studies
Aminoglycosides
Hematuria
Guanosine Triphosphate
Infection
Proteinuria
Half-Life
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Fujii, R., Fujita, K., Sakata, Y., Abe, T., Tajima, T., Terashima, I., ... Iwai, N. (1994). Clinical studies of arbekacin sulfate in the pediatric field. Japanese Journal of Antibiotics, 47(1), 57-83.

Clinical studies of arbekacin sulfate in the pediatric field. / Fujii, R.; Fujita, K.; Sakata, Y.; Abe, T.; Tajima, T.; Terashima, I.; Meguro, H.; Watanabe, N.; Mikuni, K.; Sakai, T.; Kasai, N.; Sunakawa, K.; Iwata, S.; Satoh, Y.; Akita, H.; Toyonaga, Y.; Ishihara, T.; Nakamura, H.; Iwai, N.

In: Japanese Journal of Antibiotics, Vol. 47, No. 1, 1994, p. 57-83.

Research output: Contribution to journalArticle

Fujii, R, Fujita, K, Sakata, Y, Abe, T, Tajima, T, Terashima, I, Meguro, H, Watanabe, N, Mikuni, K, Sakai, T, Kasai, N, Sunakawa, K, Iwata, S, Satoh, Y, Akita, H, Toyonaga, Y, Ishihara, T, Nakamura, H & Iwai, N 1994, 'Clinical studies of arbekacin sulfate in the pediatric field', Japanese Journal of Antibiotics, vol. 47, no. 1, pp. 57-83.
Fujii R, Fujita K, Sakata Y, Abe T, Tajima T, Terashima I et al. Clinical studies of arbekacin sulfate in the pediatric field. Japanese Journal of Antibiotics. 1994;47(1):57-83.
Fujii, R. ; Fujita, K. ; Sakata, Y. ; Abe, T. ; Tajima, T. ; Terashima, I. ; Meguro, H. ; Watanabe, N. ; Mikuni, K. ; Sakai, T. ; Kasai, N. ; Sunakawa, K. ; Iwata, S. ; Satoh, Y. ; Akita, H. ; Toyonaga, Y. ; Ishihara, T. ; Nakamura, H. ; Iwai, N. / Clinical studies of arbekacin sulfate in the pediatric field. In: Japanese Journal of Antibiotics. 1994 ; Vol. 47, No. 1. pp. 57-83.
@article{3b8e0137dd7c4d7495cf36d1fbdf1791,
title = "Clinical studies of arbekacin sulfate in the pediatric field",
abstract = "A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRSA infections (pneumonia, septicemia, etc.) of pediatric patients. The obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0{\%}. The efficacy rate by disease was 100{\%}, 50.0{\%} and 100{\%} in septicemia, pneumonia, and urinary tract infection, respectively. The bacteriological eradications were obtained in 70.0{\%} of the total patients; by disease, these rates were 100{\%} and 50.0{\%} in septicemia/urinary tract infection and in pneumonia, respectively. The MIC50 as well as the MIC80 against MRSA strains isolated from 9 patients were 0.39 μg/ml and 1.56 μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed γ-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: The pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. The C(max), 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. The T 1/2 's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5{\%} of the dosages administered. In all cases, the urinary concentrations were highest in the first 2 hours, after the administration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.",
author = "R. Fujii and K. Fujita and Y. Sakata and T. Abe and T. Tajima and I. Terashima and H. Meguro and N. Watanabe and K. Mikuni and T. Sakai and N. Kasai and K. Sunakawa and S. Iwata and Y. Satoh and H. Akita and Y. Toyonaga and T. Ishihara and H. Nakamura and N. Iwai",
year = "1994",
language = "English",
volume = "47",
pages = "57--83",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "1",

}

TY - JOUR

T1 - Clinical studies of arbekacin sulfate in the pediatric field

AU - Fujii, R.

AU - Fujita, K.

AU - Sakata, Y.

AU - Abe, T.

AU - Tajima, T.

AU - Terashima, I.

AU - Meguro, H.

AU - Watanabe, N.

AU - Mikuni, K.

AU - Sakai, T.

AU - Kasai, N.

AU - Sunakawa, K.

AU - Iwata, S.

AU - Satoh, Y.

AU - Akita, H.

AU - Toyonaga, Y.

AU - Ishihara, T.

AU - Nakamura, H.

AU - Iwai, N.

PY - 1994

Y1 - 1994

N2 - A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRSA infections (pneumonia, septicemia, etc.) of pediatric patients. The obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0%. The efficacy rate by disease was 100%, 50.0% and 100% in septicemia, pneumonia, and urinary tract infection, respectively. The bacteriological eradications were obtained in 70.0% of the total patients; by disease, these rates were 100% and 50.0% in septicemia/urinary tract infection and in pneumonia, respectively. The MIC50 as well as the MIC80 against MRSA strains isolated from 9 patients were 0.39 μg/ml and 1.56 μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed γ-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: The pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. The C(max), 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. The T 1/2 's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5% of the dosages administered. In all cases, the urinary concentrations were highest in the first 2 hours, after the administration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.

AB - A clinical investigation was carried out to evaluate arbekacin, an aminoglycoside, in the treatment of MRSA infections (pneumonia, septicemia, etc.) of pediatric patients. The obtained results are summarized as follows. 1. Clinical results: Excluding those patients who met the present exclusion criteria and withdrawal cases from a total of 18 patients, 10 patients (3, 6, and 1 cases of septicemia, pneumonia, and urinary tract infection, respectively) were subjected to clinical evaluation. These were composed of 1, 1, 6, and 2 cases of neonate, infants, pre- and school age children, respectively. Excellent, good and fair results were obtained in 5, 2, and 3 patients, respectively; thus, the efficacy rate was 70.0%. The efficacy rate by disease was 100%, 50.0% and 100% in septicemia, pneumonia, and urinary tract infection, respectively. The bacteriological eradications were obtained in 70.0% of the total patients; by disease, these rates were 100% and 50.0% in septicemia/urinary tract infection and in pneumonia, respectively. The MIC50 as well as the MIC80 against MRSA strains isolated from 9 patients were 0.39 μg/ml and 1.56 μg/ml, respectively. No adverse reactions were observed in the 15 patients, while in laboratory test values, one case each out of 12 patients examined showed γ-GTP elevation, proteinuria, and hematuria. 2. Pharmacokinetics: The pharmacokinetics of the agent was investigated in a total of 9 patients, which included 1 neonate and 4 cases each of pre- and school age children. The C(max), 4.85~8.83 μg/ml, was observed immediately after the termination of the instillation. The T 1/2 's were 4.96 hours, 1.24~2.54 hours, and 1.78~1.88 hours in the neonate, the pre- and the school age children, respectively; in the neonate the half-life was longer. When 1.92~2.7 mg/kg were administered to 3 each of the pre- and school age children, urinary excretion rates in the first 6~8 hours were 40.1~56.5% of the dosages administered. In all cases, the urinary concentrations were highest in the first 2 hours, after the administration, and then gradually decreased. These results suggest that arbekacin is a useful antibiotic for treating MRSA infections in the pediatric field.

UR - http://www.scopus.com/inward/record.url?scp=0027958511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027958511&partnerID=8YFLogxK

M3 - Article

C2 - 8114274

AN - SCOPUS:0027958511

VL - 47

SP - 57

EP - 83

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 1

ER -